Continuous Glucose Monitoring: Updated

Alefiya Faizullahbhow, MBA, MS, RD, CDCES, CDN, FAND, and Jennifer H. Argen, MS, RDN, CDN, CDCES

Introduction
Diabetes is a chronic and complicated disease in which glycemic management must be accompanied by positive behavior changes to improve clinical outcomes and quality of life. Diabetes technology continues to expand and evolve to improve the quality of lives for persons with diabetes (PWD). The rapid influx of new devices and improvements to continuous glucose monitors (CGMs) in recent years can empower patients to gain more insight for self-management, take an active role in problem solving, and lessen the burden of multiple daily fingersticks. The American Diabetes Association (ADA) has published updated principles for integrating technology and best practices for a patient-centric approach when using CGMs and devices. However, the type and selection of CGMs should be individualized based on a person's specific needs, skill level, availability, and insurance coverage. It is imperative that PWD and caregivers receive initial and ongoing education and training on the CGM device. The training must be effective either in person or virtually to ensure the patient understands how to interpret the data and share the results with the care team. Patients with additional education regarding their CGM device have improved outcomes.1

Updates in Clinical Guidelines
The ADA recommends that real-time continuous glucose monitoring or intermittently scanned continuous glucose monitoring be offered for youth and adults who are receiving multiple daily insulin injections or an insulin pump.1 A recent randomized control trial investigated the efficacy of intermittently scanned continuous glucose monitoring compared with daily fingerstick testing in a population of type 1 diabetes patients with glycated hemoglobin levels between 7.5% and 11.0%. After 24 weeks, results demonstrated significantly lower glycated hemoglobin levels among participants using intermittently scanned continuous glucose monitoring compared with those using daily fingersticks. Observational studies have demonstrated reductions in acute complications such as diabetic ketoacidosis and severe hypoglycemia in patients with type 1 diabetes who are using intermittently scanned continuous glucose monitoring. Retrospective studies of adults with type 2 diabetes who received multiple daily insulin injections and used intermittently scanned continuous glucose monitoring demonstrated reduced hospitalizations and overall increase in satisfaction compared with adults who used traditional blood glucose monitoring. Observational and retrospective studies have demonstrated clinical benefits in adults with type 2 diabetes who received basal insulin therapy and used intermittently scanned continuous glucose monitoring.1 Even patients who only received basal insulin therapy had reduced A1C levels, reduced hospitalizations, and overall increased satisfaction in their self-management. The ADA emphasizes that professional or intermittent continuous glucose monitoring should include education regarding interpretation of the results to drive behavior change and shared decision-making.1

The Endocrine Society Clinical Practice Guidelines have also incorporated CGM into recent recommendations for noncritical hospitalized patients with diabetes. In adults with insulin-treated diabetes at high risk of hypoglycemia, real-time continuous glucose monitoring is now recommended for the inpatient setting to monitor for adjustments in insulin dosing.3 Patients with hypoglycemia and hypoglycemia unawareness can be good candidates for CGMs. CGMs can be an important tool for PWD who are wholly engaged in their own self-care. CGMs should also be considered for patients with comorbid conditions, with advanced age, and with poorly managed diabetes. However, CGMs may not be accurate in the hospital setting in patients with extensive skin infections or hypovolemia or who are receiving high doses of acetaminophen or vitamin C.4 CGMs would not be appropriate for patients who are dehydrated, hypotensive, in shock, or in a hyperglycemic hyperosmolar state with or without ketosis. CGMs are also not intended for diagnosis or screening of diabetes.4

Alefiya Faizullahbhow, MBA, MS, RD, CDCES, CDN, FAND, is the Lead Diabetes Educator, Division of Endocrinology and Metabolism, at Northwell Health in New York.

Jennifer H. Argen, MS, RDN, CDN, CDCES, is a Certified Diabetes Care and Education Specialist and a registered dietitian at EmblemHealth in New York.

This publication was supported by an unrestricted grant from Abbott Diabetes Care | December 2022
The American Diabetes Association (ADA) has published updated principles for integrating technology and best practices for a patient-centric approach when using continuous glucose monitors (CGMs) and devices. However, the type and selection of CGMs should be individualized based on a person’s specific needs, skill level, availability, and insurance coverage.

**Benefits of CGMs**

The clinical utility of CGMs has been demonstrated in patients with type 1 and type 2 diabetes and in patients who are treated with intensive insulin management. Technology offers the dual benefit of convenience and the opportunity to improve health outcomes. Leveraging the technology while understanding perceptions and behaviors associated with its use is crucial. Understanding its appropriate use and awareness of the barriers that may exist in practice can potentially circumvent fragmented health care. Technology-enabled diabetes self-management education effectiveness includes communication between the person with diabetes and the health care team, patient-generated health data use and analysis, tailored education application, and individualization of feedback. The use of technology allows improved access and care between visits and prevents or reduces therapeutic inertia. Technology-enabled care and education supports population health goals and improves overall diabetes and cardiometabolic performance measures.

Mobile Health (mHealth), which has been defined as “the medical and public health practice supported by mobile devices” by the World Health Organization, is CGMs combined with smart phone apps, which can play an important role in the self-management of diabetes.

CGMs can be prescribed for personal or professional use to provide educational opportunities, aid in decision making, and provide insight into patient behaviors. Professional CGMs can be used from 3 days to 2 weeks to obtain glycemic trends. CGMs provide a continuum of blood glucose readings, with improved accuracy, factory calibration, and potential nonadjunctive use indications. The advantage of CGMs is that they can provide both real-time and predictive glucose data. Ongoing studies have highlighted the cost-effectiveness and significant HbA1C reductions with use of CGMs. CGMs can detect and alert users of immediate and impending hypoglycemia, which is a major barrier in diabetes self-management. Blood glucose monitoring can be painful and burdensome, leading to less frequency of testing.

CGMs can transmit data directly to the user’s handheld reader or smartphone app. Additionally, they enable informed decision-making regarding lifestyle behaviors and medication adjustments and allow the individual with diabetes to immediately act to mitigate current or impending acute glycemic events. The trend arrows in a CGM help individuals make better decisions and improve their lifestyle behaviors. Telehealth services allow providers to remotely follow up with their patients and provide timely treatment recommendations. CGMs that are used in practice are shown in Table 1.

**Potential Barriers with CGM Use**

It is important to acknowledge that there is a disproportionate burden of diabetes and its associated complications in historically marginalized groups such as racial and ethnic minorities and those with lower socioeconomic status. There is a need to achieve social equity and address social determinants of health domains that include socioeconomic status, neighborhood and physical environment, food environment, health care, and social context.

Structural barriers to use of CGMs include financial concerns related to insurance coverage. There is inconsistency in the medical coverage criteria for CGMs, which is constantly changing in some states; in other states, medical coverage for CGMs is unavailable. Unfortunately, there is extensive documentation required for CGM coverage, and durable medical equipment suppliers are often tasked with making a final coverage determination for CGMs, with lack of clarity from the Centers for Medicare & Medicaid Services. It is important to acknowledge patient-related barriers to the use of CGMs that may include hesitancy to wear a sensor, alarm fatigue, and misconceptions or inadequate information regarding the device. Although there are a plethora of education modules and tutorials to support patients using CGMs, common barriers arise in clinical practice. For example, patients can develop skin dermatitis or experience sensors falling off prematurely. Provider-level barriers can exist when implementing CGMs for PWD, including a lack of time to learn about, promote, or complete the detailed paperwork needed to obtain CGMs for PWD. The most common cited barrier to the use of CGMs among clinicians and patients is insurance reimbursement and cost. Prerequisite coverage for CGMs depends on insurance plan and medications and may pose a greater burden on the physician to navigate reimbursement for the patient.

**Role of the Care Manager**

The care manager plays an integral role in supporting patients who use CGMs. Care managers can help identify appropriate candidates for CGMs and collaborate with physicians and payers to help overcome the barrier of insurance reimbursement. Large randomized controlled trials have shown that CGM use is beneficial even in patients who are not receiving intensive insulin
Ultimately, the clinical benefits of CGMs depend on support and training from the multidisciplinary team, including the case manager, who should address any barriers. Care managers play a critical role in helping persons with diabetes interpret their CGM data to implement lifestyle changes.

### TABLE 1  CONTINUOUS GLUCOSE MONITORS USED IN PRACTICE

<table>
<thead>
<tr>
<th>CGM system</th>
<th>Dexcom G6</th>
<th>Eversense®</th>
<th>Freestyle Libre 14 day</th>
<th>Freestyle Libre 2</th>
<th>Freestyle Libre 3</th>
<th>Guardian™ Sensor 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Company</td>
<td>Dexcom</td>
<td>Senseonics and Ascencia Diabetes Care</td>
<td>Abbott</td>
<td>Abbott</td>
<td>Abbott</td>
<td>Medtronic</td>
</tr>
<tr>
<td>Sensor</td>
<td>Yes</td>
<td>Yes. Professionally inserted only, under the skin</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Sensor “warm up period”</td>
<td>2 hours</td>
<td>24 hours</td>
<td>1 hour</td>
<td>1 hour</td>
<td>1 hour</td>
<td>2 hours</td>
</tr>
<tr>
<td>Sensor wear</td>
<td>10 days</td>
<td>90 days</td>
<td>14 days</td>
<td>14 days</td>
<td>14 days</td>
<td>7 days</td>
</tr>
<tr>
<td>Transmitter</td>
<td>Yes. 90-day battery life</td>
<td>Yes. Removable, rechargeable, and water resistant</td>
<td>Yes. Built into sensor, making the system one piece</td>
<td>Yes. Built into sensor, making the system one piece</td>
<td>Yes. Built into sensor, making the system one piece</td>
<td>Yes.1 year with charger (battery operated)</td>
</tr>
<tr>
<td>Receiver</td>
<td>Yes, can use compatible phone app</td>
<td>Use with compatible phone app or smart watch</td>
<td>Yes, or can use compatible phone app</td>
<td>Yes, or can use compatible phone app</td>
<td>No, use with compatible phone app only</td>
<td>Insulin pump and phone app</td>
</tr>
<tr>
<td>Alerts</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Calibration with fingersticks</td>
<td>Not needed&lt;sup&gt;a&lt;/sup&gt;</td>
<td>Initialization phase: after warm-up, 4 fingerstick tests spaced 2–12 hours apart Daily: fingerstick every 12 hours</td>
<td>Not needed</td>
<td>Not needed</td>
<td>Not needed</td>
<td>2-4 calibrations/day</td>
</tr>
<tr>
<td>MARD&lt;sup&gt;b&lt;/sup&gt;</td>
<td>9.8%</td>
<td>8.5%</td>
<td>9.7%</td>
<td>9.2%</td>
<td>7.9%</td>
<td>8.7%–10.6% (site dependent)</td>
</tr>
<tr>
<td>Integration with pump</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td>How often system measures blood glucose levels</td>
<td>Every 5 minutes</td>
<td>Every 5 minutes</td>
<td>Every 1 minute</td>
<td>Every 1 minute</td>
<td>Every 1 minute</td>
<td>Every 5 minutes</td>
</tr>
<tr>
<td>Age (y) of approved indication</td>
<td>≥2</td>
<td>≥18</td>
<td>≥18</td>
<td>≥4</td>
<td>≥4</td>
<td>≥2</td>
</tr>
</tbody>
</table>

Source: Adapted from Abbott.com, Medtronic.com, Senseonics Incorporated, Dexcom.com

<sup>a</sup> Fingersticks not required as long as you enter the code number when starting the sensor; otherwise fingersticks are required. [https://www.dexcom.com/safety-information](https://www.dexcom.com/safety-information)

<sup>b</sup> MARD, mean absolute relative difference. This metric is commonly used when comparing continuous glucose monitoring systems. The smaller the MARD, the closer the CGM readings are to the reference glucose values. A larger MARD indicates a wider range between the CGM values and the reference glucose value.
The clinical utility of CGMs has been demonstrated in patients with type 1 and type 2 diabetes and in patients who are treated with intensive insulin management.

Potential Considerations of CGMs in Different Populations

Further research can also highlight benefits of using CGMs for managing prediabetes or for weight management purposes, which is currently an off-label use. Preliminary studies have demonstrated an improvement in time in range in individuals with prediabetes who are using CGMs via mobile health apps. CGMs offer clinicians the ability to tailor individualized therapeutic diet recommendations based on postprandial glycemia. The future of nutrition science will be based on precision nutrition, or counseling patients based on their unique metabolic responses to meal composition. CGMs have enabled researchers to gain a deeper understanding of various factors that affect postprandial glycemic responses, including the gut microbiome, timing of meals, and sleep.

One study showed promising results that the use of CGMs in a prediabetic population helped drive dietary changes by helping the patient visualize the effect of carbohydrates on their blood sugar. The use of CGMs was a tangible way for patients to understand the relationship between their meal compositions and blood glucose level, while increasing their awareness of perceived risk of diabetes. Ultimately, the use of CGMs coupled with dietary counseling can drive patients to elucidate the relationship between diet, activity, stress, and sleep levels to promote weight loss and prevent type 2 diabetes.

Research continues to show positive results for pregnant women using CGMs. While the U.S. Food and Drug Administration (FDA) has not authorized the use of CGMs during pregnancy in the United States, the ADA endorses CGMs to achieve A1C targets during pregnancy. The CONCEPTT trial was a randomized controlled trial that demonstrated that pregnant women with type 1 diabetes who used real-time continuous glucose monitoring improved their HgbA1C and their time in range by 7% without increasing their hypoglycemia. In addition to improving maternal blood sugar levels, using CGMs during pregnancy significantly reduced the incidence of large for gestational age infants, neonatal hypoglycemia, and neonatal intensive care unit admissions. The ADA and the American Association of Clinical Endocrinology recommend treating pregnant women with type 1 and type 2 diabetes with intensive insulin therapy and using CGMs to improve glycemic control and neonatal outcomes. The use of real-time continuous glucose monitoring has not been well studied in clinical trials, but a large prospective cohort study of real-time continuous glucose monitoring in patients with gestational diabetes showed significantly improved daily blood glucose levels and lower glycemic variability compared with self-monitoring of blood glucose.

Conclusion

Technology confers many benefits to PWD, and the technology for CGMs is rapidly evolving to ease the burden of monitoring. Ultimately, the clinical benefits of CGMs depend on support and training from the multidisciplinary team, including the case manager, who should address any barriers. Care managers play a critical role in helping PWD interpret their CGM data to implement lifestyle changes. Technology is only as valuable as the patient’s perceived understanding of glycemic data and the problem-solving strategies to make timely treatment decisions. There are significant research opportunities for determining the effectiveness of CGMs in various populations, including patients with prediabetes, patients who need weight management, and pregnant patients. Broadening access and insurance reimbursement for CGMs will ensure that technology is equitable among PWD.

References

1. American Diabetes Association Professional Practice Committee; 7. Diabetes Technology: Standards of Medical Care in Diabetes—2022. Diabetes Care 1 January 2022; 45 (Supplement_1); S97–S112. https://doi.org/10.2337/dc22-S007


7. Kruger DF, Anderson JE. Continuous glucose monitoring (CGM) is a tool, not a reward: unjustified insurance coverage criteria limit access to CGM. *Diabetes Technol Ther.* 2021 Sep;23(S3):S45-S55. doi: 10.1089/dia.2021.0193.


Continuous Glucose Monitoring: Updated

Take the test online and then immediately print your certificate after successfully completing the test. Or print, complete, and mail the exam on the next page.

Exam expires December 21, 2023.

This exam is FREE to all. Click here to join ACCM and get access to more CEUs—up to 18 per year!

Questions

1. Continuous glucose monitoring can benefit people with diabetes by:
   a. Encouraging patients to gain more insight for self-management
   b. Empowering patients to take an active role in problem solving
   c. Lessening the burden of multiple daily fingersticks
   d. All of the above

2. The selection of continuous glucose monitors (CGMs) should be:
   a. Individualized for each patient
   b. Based on availability
   c. Based on insurance coverage
   d. All of the above

3. Training patients to ensure understanding of how to interpret data from CGMs is vital.
   a. True
   b. False

4. The American Diabetes Association recommends that real-time continuous glucose monitoring be offered to which of the following individuals?
   a. Any person with diabetes
   b. Only people with type 1 diabetes
   c. Only people with type 2 diabetes
   d. Youth and adults who are receiving multiple daily insulin injections

5. Compared with daily fingersticks, the use of CGMs can lower glycated hemoglobin levels.
   a. True
   b. False

6. Studies using CGMs have demonstrated which of the following for people with diabetes?
   a. Reductions in acute complications
   b. Reduced hospitalizations
   c. Increase in patient satisfaction
   d. All of the above

7. Patients with hypoglycemia and hypoglycemia unawareness are good candidates for CGMs.
   a. True
   b. False

8. CGMs are not appropriate for which of the following patients?
   a. Dehydrated patients
   b. Hypotensive patients
   c. Patients in shock
   d. All of the above

9. Technology-enabled diabetes self-management education effectiveness includes which of the following?
   a. Communication between patient and care team
   b. Patient-generated health data use and analysis
   c. Tailored education
   d. All of the above

10. The use of continuous glucose monitoring technology allows improved access and care between visits.
    a. True
    b. False

11. Which of the following social determinants of health are applicable to patients with diabetes who use continuous glucose monitoring?
    a. Socioeconomic status
    b. Food environment
    c. Neighborhood
    d. All of the above

12. Which of the following are patient-centered barriers to the use of CGMs?
    a. Hesitancy to wear a sensor
    b. Alarm fatigue
    c. Misconception or inadequate information about the device
    d. All of the above

13. The role of the case manager in working with CGMs includes which of the following?
    a. Identifying appropriate candidates for CGMs
    b. Overcoming insurance barriers
    c. Educating patients and caregivers
    d. All of the above
Continuous Glucose Monitoring: Updated

Objectives

1. State how diabetes technology has improved outcomes for people with diabetes.
2. State three benefits of continuous glucose monitoring.
3. State three potential barriers to use of continuous glucose monitoring.

Answers

Please indicate your answer by filling in in the letter:


Continuing Education Program Evaluation

Please indicate your rating by circling the appropriate number using a scale of 1 (low) to 5 (high).

1. The objectives were met. 1 2 3 4 5
2. The article was clear and well organized. 1 2 3 4 5
3. The topic was both relevant and interesting to me. 1 2 3 4 5
4. The amount and depth of the material were adequate. 1 2 3 4 5
5. The quality and amount of the graphics were effective. 1 2 3 4 5
6. I would recommend this article. 1 2 3 4 5
7. This has been an effective way to present continuing education. 1 2 3 4 5
8. Additional comments: ____________________________________________________________________________________

Please print:

*Certificant’s Name: _________________________________________
*Email Address: _____________________________________________
*Mailing Address: ____________________________________________
____________________________________________________________________________________
____________________________________________________________________________________
____________________________________________________________________________________

*CE exams cannot be processed without above information.

Please complete all that apply:

☐ CCM ID# __________________________
☐ CMSA ID# __________________________
☐ CDMS ID# __________________________
☐ RN ID# __________________________
☐ ACCM Membership# __________________________

ACCM Exp. Date __________________________

CE contact hours applied for: ☐ CCM ☐ RN ☐ CDMS

This educational manuscript has been approved for 1 hour of CCM and CDMS education credit by The Commission for Case Manager Certification and the Certification of Disability Management Specialists Commission. Provider #00059431. It has also been approved for 1 contact hour of nursing credit by the California Board of Registered Nursing. To receive credit for this exam, you must score 80% or above. Exam expires December 21, 2023.

PLEASE NOTE: Exam may be taken online at www.academyCCM.org/ce or by clicking the link found in this supplement. Take the exam and immediately print your certificate after successfully completing the test. Mailed exams should be sent to: Academy of Certified Case Managers, 1574 Coburg Road #225, Eugene, Oregon 97401. Please allow 4 to 6 weeks for processing of mailed exams.

This CE exam is protected by U.S. Copyright law. You are permitted to make one copy for the purpose of exam submission. Multiple copies are not permitted.

If you are not an ACCM member and wish to become one, please click here.